Loredana Lorusso
University of Pisa
35 Papers
28 Citations
Loredana Lorusso is an academic researcher from University of Pisa. The author has contributed to research in topics: Medicine & Thyroid cancer. The author has an hindex of 9, co-authored 24 publications. Previous affiliations of Loredana Lorusso include World Health Organization.
Chat about Author
Papers
Treatment of advanced thyroid cancer with targeted therapies: ten years of experience
David Viola,Laura Valerio,Eleonora Molinaro,Laura Agate,Valeria Bottici,Agnese Biagini,Loredana Lorusso,Virginia Cappagli,Letizia Pieruzzi,Carlotta Giani,Elena Sabini,Paolo Passannati,Luciana Puleo,Antonio Matrone,Benedetta Pontillo-Contillo,Valentina Battaglia,Salvatore Mazzeo,Paolo Vitti,Rossella Elisei +18 more
TL;DR: The objective of this review is to present the current status of the treatment of advanced thyroid cancer with the use of innovative targeted therapies by describing both the benefits and the limits of their use based on the experiences reported so far.
Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center
Eleonora Molinaro,Maria Cristina Campopiano,Letizia Pieruzzi,Antonio Matrone,Laura Agate,Valeria Bottici,David Viola,Virginia Cappagli,Laura Valerio,Carlotta Giani,Luciana Puleo,Loredana Lorusso,Paolo Piaggi,Liborio Torregrossa,Fulvio Basolo,Paolo Vitti,R. Michael Tuttle,Rossella Elisei +17 more
TL;DR: Within an Italian medical context, active surveillance appears to be a feasible and safe alternative to immediate surgery in healthy mPTC patients and importantly demonstrated excellent outcomes after surgical intervention in a short term follow up.
132
•Journal Article
New and old knowledge on differentiated thyroid cancer epidemiology and risk factors.
TL;DR: In the last years it has been observed an important change in the oncogenic pattern of PTC with a significant reduction of RET/PTC rearrangements and an increase of BRAFV600E mutation suggesting a change in pathogenic events.
68
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations.
Rossella Elisei,Alessia Tacito,Teresa Ramone,Raffaele Ciampi,Valeria Bottici,Virginia Cappagli,David Viola,Antonio Matrone,Loredana Lorusso,Laura Valerio,Carlotta Giani,Cristina Campopiano,Alessandro Prete,Laura Agate,Eleonora Molinaro,Cristina Romei +15 more
TL;DR: The V804M mutation was the most prevalent in this cohort, especially in cases that presented as sporadic, while mutations affecting cysteine residues were the most frequent in the group of clinically hereditary cases.
67
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
Loredana Lorusso,Letizia Pieruzzi,Agnese Biagini,Elena Sabini,Laura Valerio,Carlotta Giani,Paolo Passannanti,Benedetta Pontillo-Contillo,Valentina Battaglia,Salvatore Mazzeo,Eleonora Molinaro,Rossella Elisei +11 more
TL;DR: The results of the main studies on lenvatinib efficacy in patients with advanced and progressive thyroid cancer, mainly in DTCs but also in medullary and anaplastic thyroid cancer are reported and the efficacy of other tyrosine kinase inhibitors are compared.